Unique ID issued by UMIN | UMIN000043341 |
---|---|
Receipt number | R000049484 |
Scientific Title | The effects of ingestion of Panax genus plants, extracts, or ginseno-sides intake on exercise endurance- A systematic review with Me-ta-analysis. |
Date of disclosure of the study information | 2021/04/01 |
Last modified on | 2022/03/14 15:36:09 |
The effects of ingestion of Panax genus plants, extracts, or ginsenosides intake on exercise endurance- A systematic review with Meta-analysis.
A systematic review of Panax genus plants or ginsenosides.
The effects of ingestion of Panax genus plants, extracts, or ginseno-sides intake on exercise endurance- A systematic review with Me-ta-analysis.
A systematic review of Panax genus plants or ginsenosides.
Japan |
Adult volunteers who have no problems with motor and metabolic functions.
Adult |
Others
NO
The object of this review is to evaluate the effect on exercise endurance by ingestion of food containing Panax genus plants, extracts or ginsenosides compared with the intake of placebo food.
Efficacy
Not applicable
Exercise endurance.
Others,meta-analysis etc
18 | years-old | <= |
Not applicable |
Male and Female
Participants: Adult volunteers who have no problems with motor and metabolic functions. *1
Intervention: One-time or continuous intake of food containing Panax genus plants, or their extract (more than 100mg/day), or ginsenosides (more than 4mg/day) *2
Comparison: Intake of placebo food.
Outcome:
Primary outcome: exercise endurance.
Study design: randomized, double-blind, placebo-controlled parallel group trial / randomized, double-blinded, placebo-controlled cross-over trial/ quasi-randomized, double-blind, placebo-controlled controlled trial.
The literature to be included will be made up of original papers, information on clinical trial registered databases, abstracts, and grey literature.
The keywords used in the literature search will be in English or Japanese only. Hand-search will also be conducted on some scientific journals.
*1: Studies with participants who have characteristic exercise ability like athletes, belong sports teams or military will be included but will be subgroup analysis.
Studies with participants who have disease or illness will be included, except those affected by disease impacting their physical exercise ability. Participants with diseases related to motor function of the limbs judged to have physical exercise ability will be included.
*2: According to previous study, single intake and continuous intake up to 12 weeks was included.
Literature which does not meet key inclusion criteria will be excluded.
Participants who are planning or currently pregnant or breastfeeding, and children (persons under 18 years), will be excluded from this study. If participants have conditions such as any acute or chronic diseases: cardiovascular, pulmonary, endocrine system, gastrointestinal system, and other organ dysfunction, or cancer, they will be excluded.
The studies will be excluded from using special dosage form food like foods to avoid digestion or absorption by the gastrointestinal system as intervention foods.
For the control group, no intervention is excluded.
Literature not written in English or Japanese will be excluded due to inability to verify and perform data extraction.
1st name | Shingo |
Middle name | |
Last name | Ikeuchi |
Maruzen Pharmaceuticals Co.,Ltd.
Research & Development div.
729-3102
1089-8, Sagata, Shinnichi-cho, Fukuyama city, Hiroshima, Japan
0847526262
s-ikeuchi@maruzenpcy.co.jp
1st name | Shingo |
Middle name | |
Last name | Ikeuchi |
Maruzen Pharmaceuticals Co.,Ltd.
Research & Development div.
729-3102
1089-8, Sagata, Shinnichi-cho, Fukuyama city, Hiroshima, Japan
0847526262
s-ikeuchi@maruzenpcy.co.jp
Maruzen Pharmaceuticals Co., LTD.
Maruzen Pharmaceuticals Co., LTD.
Profit organization
Professor
Hiroharu Kamioka, Graduate School of Tokyo University of Agriculture
The lead principal investigator is enrolled in the doctoral program at the Graduate School of Tokyo University of Agriculture.
NA
NA
NA
NA@NA
NO
2021 | Year | 04 | Month | 01 | Day |
Published
https://www.mdpi.com/2072-6643/14/6/1185
123
Main results already published
2021 | Year | 02 | Month | 15 | Day |
2021 | Year | 02 | Month | 15 | Day |
2021 | Year | 02 | Month | 15 | Day |
2021 | Year | 03 | Month | 31 | Day |
(Search)
Reviewer A, searcher B, and an outsourcing searcher will search 12 databases and 3 internet search engines for studies from the beginning of each database to the search date.
Reviewers A and C will independently search journals in the possession of Maruzen Pharmaceuticals Co., Ltd.
(Data extraction)
Reviewers A and C will independently apply all criteria to the full text of articles that have passed the first eligibility screening. Disagreement and uncertainties will be resolved by discussion with researcher D.
(Risk of bias assessment and Indirectness evaluation)
Reviewers A and C will independently assess the quality of articles and evaluate the indirectness of articles. A full quality appraisal of these papers will be made using a check list (7 items) from the Cochrane Handbook for interventional trials.
Disagreements and uncertainties will be resolved by discussion with researcher D.
(Meta-analysis)
Only when no or limited heterogeneity is found in multiple randomized controlled trials, will reviewers A and C perform a meta-analysis of Panax species using RevMan 5.3.
After the meta-analysis is carried out, the results will be confirmed by research collaborator E, who is an expert in systematic review.
Meta-analysis will be conducted with a random effect model considering the differences among studies, using standardized mean difference for effect estimate and 95%CI. Estimated heterogeneity will be judged with forest plot, P or Cochrane Q, and I2.
Additional analysis will be performed according to the characteristics of the literature to be evaluated.
(Other bias risk)
Imprecision, inconsistency, and publication bias of this study will be evaluated with the GRADE system.
(Protocol)
The protocol of this study cannot be completely explained here because of limitations of this site. Protocol details are archived at the organization of the "Principal investigator". For full protocol details, contact the "Contact person" directly.
2021 | Year | 02 | Month | 16 | Day |
2022 | Year | 03 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049484
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |